These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32476539)

  • 41. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study.
    Christensen AM; Bjerre J; Schou M; Jons C; Vinther M; Gislason GH; Johansen JB; Nielsen JC; Petersen HH; Riahi S; Ruwald AC
    Europace; 2019 Mar; 21(3):465-474. PubMed ID: 30535192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of Appropriate Therapy and Death Before Therapy After Implantable Cardioverter-Defibrillator Generator Replacement.
    Witt CM; Waks JW; Mehta RA; Friedman PA; Kramer DB; Buxton AE; Mulpuru SK; Noseworthy PA; Hodge DO; Lushinsky EC; Mulholland MB; Cha YM; Gersh BJ; Madhavan M
    Circ Arrhythm Electrophysiol; 2018 Aug; 11(8):e006155. PubMed ID: 30354311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators.
    Bansal N; Szpiro A; Masoudi F; Greenlee RT; Smith DH; Magid DJ; Gurwitz JH; Reynolds K; Tabada GH; Sung SH; Dighe A; Cassidy-Bushrow A; Garcia-Montilla R; Hammill S; Hayes J; Kadish A; Sharma P; Varosy P; Vidaillet H; Go AS
    Heart; 2017 Apr; 103(7):529-537. PubMed ID: 27742796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%.
    Al-Khatib SM; Hellkamp AS; Fonarow GC; Mark DB; Curtis LH; Hernandez AF; Anstrom KJ; Peterson ED; Sanders GD; Al-Khalidi HR; Hammill BG; Heidenreich PA; Hammill SC
    JAMA; 2014 Jun; 311(21):2209-15. PubMed ID: 24893088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective observational study of implantable cardioverter-defibrillators in primary prevention of sudden cardiac death: study design and cohort description.
    Cheng A; Dalal D; Butcher B; Norgard S; Zhang Y; Dickfeld T; Eldadah ZA; Ellenbogen KA; Guallar E; Tomaselli GF
    J Am Heart Assoc; 2013 Feb; 2(1):e000083. PubMed ID: 23525420
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Stavrakis S; Asad Z; Reynolds D
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Improved Left Ventricular Systolic Function on the Recurrence of Ventricular Arrhythmia in Heart Failure Patients With an Implantable Cardioverter-Defibrillator.
    Kim M; Kim J; Lee JH; Hwang YM; Kim MS; Nam GB; Choi KJ; Kim JJ; Kim YH
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1191-1198. PubMed ID: 27334231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting Risk Versus Predicting Potential Survival Benefit Using 123I-mIBG Imaging in Patients With Systolic Dysfunction Eligible for Implantable Cardiac Defibrillator Implantation: Analysis of Data From the Prospective ADMIRE-HF Study.
    Hachamovitch R; Nutter B; Menon V; Cerqueira MD
    Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26666380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
    Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
    BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
    Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
    Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction.
    Jilek C; Lewalter T; Pauschinger M; von Scheidt W; Frankenstein L; Pfister O; Hambrecht R; Bruder O; Brachmann J; Hartmann A; Strasser R; Hochadel M; Senges J
    Clin Res Cardiol; 2020 Jan; 109(1):115-123. PubMed ID: 31236690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Left Ventricular Entropy Is a Novel Predictor of Arrhythmic Events in Patients With Dilated Cardiomyopathy Receiving Defibrillators for Primary Prevention.
    Muthalaly RG; Kwong RY; John RM; van der Geest RJ; Tao Q; Schaeffer B; Tanigawa S; Nakamura T; Kaneko K; Tedrow UB; Stevenson WG; Epstein LM; Kapur S; Zei PC; Koplan BA
    JACC Cardiovasc Imaging; 2019 Jul; 12(7 Pt 1):1177-1184. PubMed ID: 30121262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal study of implantable cardioverter-defibrillators: methods and clinical characteristics of patients receiving implantable cardioverter-defibrillators for primary prevention in contemporary practice.
    Masoudi FA; Go AS; Magid DJ; Cassidy-Bushrow AE; Doris JM; Fiocchi F; Garcia-Montilla R; Glenn KA; Goldberg RJ; Gupta N; Gurwitz JH; Hammill SC; Hayes JJ; Jackson N; Kadish A; Lauer M; Miller AW; Multerer D; Peterson PN; Reifler LM; Reynolds K; Saczynski JS; Schuger C; Sharma PP; Smith DH; Suits M; Sung SH; Varosy PD; Vidaillet HJ; Greenlee RT
    Circ Cardiovasc Qual Outcomes; 2012 Nov; 5(6):e78-85. PubMed ID: 23170006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ambulatory blood pressure monitoring, 2D-echo and clinical variables relating to cardiac events in ischaemic cardiomyopathy following cardioverter-defibrillator implantation.
    Antonini L; Pasceri V; Mollica C; Ficili S; Poti G; Aquilani S; Santini M; La Rocca S
    J Cardiovasc Med (Hagerstown); 2011 May; 12(5):334-9. PubMed ID: 21487343
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization.
    Goldstein SA; Li S; Lu D; Matsouaka RA; Rymer J; Fonarow GC; de Lemos JA; Peterson E; Pokorney SD; Wang T; Al-Khatib SM
    Am J Cardiol; 2021 Jan; 138():26-32. PubMed ID: 33068540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.